Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Other Accumulated Expenses: 2022-2024

Historic Other Accumulated Expenses for Mereo BioPharma Group (MREO) over the last 3 years, with Dec 2024 value amounting to $1.1 million.

  • Mereo BioPharma Group's Other Accumulated Expenses fell 76.48% to $622,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $622,000, marking a year-over-year decrease of 76.48%. This contributed to the annual value of $1.1 million for FY2024, which is 7.25% up from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's Other Accumulated Expenses is $1.1 million, which was up 7.25% from $1.0 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Other Accumulated Expenses ranged from a high of $1.1 million in FY2024 and a low of $1.0 million during FY2023.
  • Its 3-year average for Other Accumulated Expenses is $1.1 million, with a median of $1.1 million in 2022.
  • In the last 5 years, Mereo BioPharma Group's Other Accumulated Expenses fell by 4.67% in 2023 and then increased by 7.25% in 2024.
  • Mereo BioPharma Group's Other Accumulated Expenses (Yearly) stood at $1.1 million in 2022, then dropped by 4.67% to $1.0 million in 2023, then increased by 7.25% to $1.1 million in 2024.